Key result
In Japanese patients with high cardiovascular risk, 27% were low-responders to aspirin, and the antiplatelet effect of aspirin did not decrease after a 2-year follow-up.
Why the study?
Does the antiplatelet effect of aspirin diminish after 2 years of treatment in Japanese patients?
Observational (n=264)
No
Does the antiplatelet effect of aspirin diminish after 2 years of treatment in Japanese patients?
In Japanese patients on aspirin monotherapy, 27% exhibit low responsiveness, but the antiplatelet effect remains stable over a 2-year period.
Aspirin responsiveness stability over 2 years may reassure on monitoring; leaves open outcome impact of low responders in Japanese cohorts.
BACKGROUND: Aspirin is an antiplatelet drug widely used for the prevention of cardiovascular diseases. It has been reported that some patients who exhibit a reduced antiplatelet effect of aspirin have higher cardiovascular risk. It is still controversial whether the antiplatelet effect of aspirin diminishes after a few years of treatment. This study aimed to evaluate the antiplatelet effect of aspirin and its 2-year change in Japanese patients. METHODS AND RESULTS: Collagen-induced platelet-aggregability was measured at enrollment by conventional optical aggregometer in 239 patients undergoing antiplatelet therapy with aspirin alone. Among them, 167 patients were evaluated after 2 years. Whole blood aggregability based on the screen-filtration method was also evaluated. Optical aggregometer studies showed that 27% of patients were low-responders. Multivariate analyses revealed that female sex and non-use of calcium-channel blockers were associated with low responsiveness. The antiplatelet effect of aspirin did not decrease after 2 years. Similar data were obtained with the whole blood aggregometer. CONCLUSIONS: In this Japanese patient group, 27% were low-responders to aspirin, and the antiplatelet effect of aspirin did not decrease after a 2-year interval.
No takes yet. Share an insight, caveat, or question.
Ikeda et al. (2010) conducted an observational in High cardiovascular risk (n=264). Aspirin therapy vs. Baseline (enrollment) or Control group (no antiplatelet drugs) was evaluated on Prevalence of low-responders to aspirin (PRP-PATI <1.0 mg/L). In Japanese patients with high cardiovascular risk, 27% were low-responders to aspirin, and the antiplatelet effect of aspirin did not decrease after a 2-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: